Posted by Michael Wonder on 18 Aug 2025
Marketing authorisation application for CT001 has been submitted to the EMA for acute pain management in children
14 August 2025 - The marketing authorisation application for CT001 is submitted to the EMA for acute pain management in children.
Proveca has submitted a paediatric use marketing authorisation application for CT001 (ketamine/sufentanil nasal spray) to the EMA.
